Ruby Birk

877 total citations
14 papers, 349 citations indexed

About

Ruby Birk is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Infectious Diseases. According to data from OpenAlex, Ruby Birk has authored 14 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 12 papers in Physiology and 0 papers in Infectious Diseases. Recurrent topics in Ruby Birk's work include Chronic Obstructive Pulmonary Disease (COPD) Research (13 papers), Asthma and respiratory diseases (12 papers) and Inhalation and Respiratory Drug Delivery (9 papers). Ruby Birk is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (13 papers), Asthma and respiratory diseases (12 papers) and Inhalation and Respiratory Drug Delivery (9 papers). Ruby Birk collaborates with scholars based in United States, United Kingdom and Germany. Ruby Birk's co-authors include David A. Lipson, Noushin Brealey, Chang‐Qing Zhu, Maggie Tabberer, David A. Lomas, Nicholas Locantore, Helen Barnacle, Rajat Mohindra, Steven Pascoe and Andrea Ludwig-Sengpiel and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Clinical Pharmacokinetics and Respiratory Research.

In The Last Decade

Ruby Birk

13 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruby Birk United States 6 339 258 13 13 10 14 349
Ferran Chuecos Spain 9 295 0.9× 240 0.9× 10 0.8× 11 0.8× 9 0.9× 20 324
Rajat Mohindra United Kingdom 5 281 0.8× 217 0.8× 10 0.8× 13 1.0× 6 0.6× 7 304
Christie Arrasate United Kingdom 3 398 1.2× 307 1.2× 13 1.0× 19 1.5× 3 0.3× 6 411
В Е Ноников Russia 3 472 1.4× 401 1.6× 14 1.1× 12 0.9× 12 1.2× 5 494
Chris Compton United States 10 438 1.3× 306 1.2× 7 0.5× 14 1.1× 12 1.2× 46 460
Catherine Francisco Italy 4 610 1.8× 482 1.9× 15 1.2× 28 2.2× 8 0.8× 6 628
H Prunier Italy 2 390 1.2× 299 1.2× 11 0.8× 15 1.2× 7 0.7× 4 399
Alessandro Guasconi Italy 6 474 1.4× 357 1.4× 11 0.8× 17 1.3× 7 0.7× 23 493
Chris Compton United States 11 333 1.0× 270 1.0× 3 0.2× 23 1.8× 6 0.6× 29 345
Kiernan DeAngelis United States 8 346 1.0× 255 1.0× 2 0.2× 11 0.8× 7 0.7× 17 360

Countries citing papers authored by Ruby Birk

Since Specialization
Citations

This map shows the geographic impact of Ruby Birk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruby Birk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruby Birk more than expected).

Fields of papers citing papers by Ruby Birk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruby Birk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruby Birk. The network helps show where Ruby Birk may publish in the future.

Co-authorship network of co-authors of Ruby Birk

This figure shows the co-authorship network connecting the top 25 collaborators of Ruby Birk. A scholar is included among the top collaborators of Ruby Birk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruby Birk. Ruby Birk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
3.
4.
5.
Halpin, David, Ruby Birk, Noushin Brealey, et al.. (2018). Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Research. 4(2). 119–2017. 13 indexed citations
6.
Naya, Ian, Chris Compton, Afisi Ismaila, et al.. (2018). Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Research. 4(4). 47–2018. 18 indexed citations
7.
Tabberer, Maggie, David A. Lomas, Ruby Birk, et al.. (2018). Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life. Advances in Therapy. 35(1). 56–71. 21 indexed citations
8.
Mehta, Rashmi, Misba Beerahee, Noushin Brealey, et al.. (2018). Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD. The Journal of Clinical Pharmacology. 58(11). 1461–1467. 3 indexed citations
9.
Lipson, David A., Helen Barnacle, Ruby Birk, et al.. (2017). FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 196(4). 438–446. 226 indexed citations
10.
Ismaila, Afisi, Ruby Birk, Dhvani Shah, et al.. (2017). Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial. Advances in Therapy. 34(9). 2163–2172. 13 indexed citations
11.
12.
Naya, Ian, Helen Barnacle, Ruby Birk, et al.. (2017). Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study. PA3248–PA3248. 3 indexed citations
13.
Lipson, David A., Helen Barnacle, Ruby Birk, et al.. (2017). Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses. PA1057–PA1057. 2 indexed citations
14.
Lomas, David A., David A. Lipson, Helen Barnacle, et al.. (2016). LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial. PA4629–PA4629. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ferran Chuecos Breakdown of academic impact, for papers by Rajat Mohindra Breakdown of academic impact, for papers by Christie Arrasate Breakdown of academic impact, for papers by В Е Ноников Breakdown of academic impact, for papers by Chris Compton Breakdown of academic impact, for papers by Catherine Francisco Breakdown of academic impact, for papers by H Prunier Breakdown of academic impact, for papers by Alessandro Guasconi Breakdown of academic impact, for papers by Chris Compton Breakdown of academic impact, for papers by Kiernan DeAngelis
Rankless by CCL
2026